This is a promising result in renoprotection and warrants more extensive studies over a longer duration to clarify the superiority of combined GLP-1-glucagon agonist in nephropathy compared to GLP-1 RA agonist alone [182]. This evidence concerns the gene GLP1R and Nephropathy.